Compare Adaptive Biotechnologies Corp (ADPT) vs Northrop Grumman Corporation (NOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Northrop Grumman Corporation — how do they compare? Adaptive Biotechnologies Corp trades at $25.57 (market cap $4.04B), while Northrop Grumman Corporation trades at $574 (market cap $81.78B). The key difference: Northrop Grumman Corporation is far larger — about 20.2× Adaptive Biotechnologies Corp's market cap, and Northrop Grumman Corporation pays a 1.63% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | NOC | |
|---|---|---|
Market Cap | $4.04B | $81.78B |
Sector | Health | Industrials |
52-Week High | $25.45 | $768.02 |
52-Week Low | $12.30 | $496.02 |
Enterprise Value | $4.10B | $95.77B |
Dividend Yield | — | 1.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.
Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.
Northrop Grumman (NOC) trades at $577.89, up 1.1% today, with a bullish technical signal from moving averages and a record $105 billion backlog supporting fundamentals. Recent Q2 2026 earnings beat expectations, with sales growth of 5% and raised full-year guidance (Seeking Alpha, 2026-07-23). Valuation ratios like P/E of 18.3 and ROE of 26.96% reflect strong profitability, though RSI levels indicate overbought conditions.
The outlook is positive due to defense spending tailwinds and strategic contracts, but risks include margin pressure from specific programs and geopolitical volatility. Analysts maintain a buy consensus with a $598.57 price target, suggesting modest upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →
